On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 2023 earnings per share (EPS) of -$0.29, up 1,066.67% year over year. Total Supernus Pharmaceuticals earnings for the quarter were -$15.98 million. In the same quarter last year, Supernus Pharmaceuticals's earnings per share (EPS) was $0.03.
As of Q4 2023, Supernus Pharmaceuticals's earnings has grown -33.8% year over year. This is 48.99 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 15.19%. Supernus Pharmaceuticals's earnings in the past year totalled $25.62 million.
What was SUPN's revenue last quarter?
On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 2023 revenue of $153.88 million up 13.24% year over year. In the same quarter last year, Supernus Pharmaceuticals's revenue was $177.35 million.
What was SUPN's revenue growth in the past year?
As of Q4 2023, Supernus Pharmaceuticals's revenue has grown -7.35% year over year. This is 18.28 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.93%. Supernus Pharmaceuticals's revenue in the past year totalled $610.54 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.